Cardiovascular prescribing costs, England, 20025
| Total prescribing costs | £6.84 billion |
| Cardiovascular drug costs | £1.74 billion |
| Bendrofluazide | £21 million |
| β Blockers | £89 million |
| Atenolol | £21 million |
| ACE inhibitors/angiotensin receptor blockers | £500 million |
| Calcium channel blockers | £290 million |
| Amlodipine | £140 million |